Testing MST-168 in advanced solid cancers
Part of Cancer clinical trials.
This early-stage trial tests whether a new drug called MST-168 can help people with advanced solid cancers (like lung, stomach, or colon cancer) that haven't responded to standard treatments. You'll receive the drug to see if it's safe and if it helps slow or stop your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- At least 18 years old
- Advanced cancer (solid tumor) that has not responded to or cannot tolerate standard treatments
- Good overall health and ability to care for yourself (ECOG score 0 or 1)
- Expected to live at least 12 weeks
- Adequate organ function (kidneys, liver, heart, etc.)
- Willing to use effective birth control for 6 months after treatment (if able to become pregnant or have a partner who can)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.
This early-stage study tests an investigational drug (MHB088C) in adults with advanced or metastatic solid cancers that have gotten worse or can’t be treated with standard options. It aims to see if the drug is safe and can shrink tumors or control the cancer.
This trial tests a new treatment called 'microtransplantation' for people with advanced or relapsed solid tumors. It aims to see if this approach can help shrink tumors or slow their growth while keeping side effects manageable.
This trial tests a new drug called JMT108 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to see if the drug is safe and how it affects the body.
Hear when a new Neoplams trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.